PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Takeda Spins Out Investigational Stress Urinary Incontinence Drug to Yamada-Led US Firm
March 16, 2016
- Ethical Drug Sales Up 7.0% in January: Crecon Report
March 15, 2016
- Lilly Seeks to Block Launch of Evista Generics Approved in February
March 15, 2016
- AbbVie Launches Japan PIII Trials for All Hep C Genotypes
March 15, 2016
- MSD Files 2 Antivirals for Hep C Treatment in Japan
March 14, 2016
- Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
- Mitsubishi Tanabe to Solely Market Janssen’s Simponi in Japan
March 11, 2016
- Takecab Most Heavily Pitched Drug in January: Anterio
March 11, 2016
- Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
- Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
March 9, 2016
- Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
March 8, 2016
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
- NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
March 7, 2016
- Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
March 4, 2016
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…